CN106573897B - 作为mIDH1抑制剂的苯并咪唑-2-胺 - Google Patents

作为mIDH1抑制剂的苯并咪唑-2-胺 Download PDF

Info

Publication number
CN106573897B
CN106573897B CN201580019265.9A CN201580019265A CN106573897B CN 106573897 B CN106573897 B CN 106573897B CN 201580019265 A CN201580019265 A CN 201580019265A CN 106573897 B CN106573897 B CN 106573897B
Authority
CN
China
Prior art keywords
amino
phenyl
trimethylcyclohexyl
alkyl
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580019265.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573897A (zh
Inventor
H.雷文克尔
O.潘克宁
S.林格
S.安劳夫
H.西贝奈歇尔
D.阮
W.施维德
M.鲍泽
K.齐默曼
S.考尔富斯
R.诺伊豪斯
P.M.布拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106573897(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN106573897A publication Critical patent/CN106573897A/zh
Application granted granted Critical
Publication of CN106573897B publication Critical patent/CN106573897B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580019265.9A 2014-02-11 2015-02-10 作为mIDH1抑制剂的苯并咪唑-2-胺 Expired - Fee Related CN106573897B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14154680.4 2014-02-11
EP14154680 2014-02-11
EP14182002 2014-08-22
EP14182002.7 2014-08-22
PCT/EP2015/052676 WO2015121210A1 (en) 2014-02-11 2015-02-10 Benzimidazol-2-amines as midh1 inhibitors

Publications (2)

Publication Number Publication Date
CN106573897A CN106573897A (zh) 2017-04-19
CN106573897B true CN106573897B (zh) 2019-09-24

Family

ID=52462928

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580019265.9A Expired - Fee Related CN106573897B (zh) 2014-02-11 2015-02-10 作为mIDH1抑制剂的苯并咪唑-2-胺

Country Status (23)

Country Link
US (2) US9957235B2 (enExample)
EP (1) EP3105209B1 (enExample)
JP (1) JP6534675B2 (enExample)
KR (1) KR20160115991A (enExample)
CN (1) CN106573897B (enExample)
AP (1) AP2016009371A0 (enExample)
AU (1) AU2015217788B2 (enExample)
BR (1) BR112016018604A2 (enExample)
CA (1) CA2939026A1 (enExample)
CL (1) CL2016002033A1 (enExample)
CR (1) CR20160361A (enExample)
CU (1) CU24410B1 (enExample)
DO (1) DOP2016000208A (enExample)
EA (1) EA031655B1 (enExample)
IL (1) IL246785A0 (enExample)
MX (1) MX2016010474A (enExample)
PE (1) PE20170143A1 (enExample)
PH (1) PH12016501581A1 (enExample)
SG (1) SG11201605810WA (enExample)
SV (1) SV2016005257A (enExample)
TW (1) TWI666202B (enExample)
UY (1) UY35991A (enExample)
WO (1) WO2015121210A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605810WA (en) 2014-02-11 2016-08-30 Bayer Pharma AG Benzimidazol-2-amines as midh1 inhibitors
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
PT3733662T (pt) 2014-09-19 2023-08-18 Forma Therapeutics Inc Derivados piridin-2(1h)-ona-quinolinona como inibidores de isocitrato desidrogenase mutante
ES2768694T3 (es) 2014-09-19 2020-06-23 Forma Therapeutics Inc Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
CA2965201A1 (en) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CN107108554B (zh) * 2014-10-23 2020-11-06 德国癌症研究中心 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
JP6830909B2 (ja) * 2015-06-08 2021-02-17 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール
ES2877424T3 (es) 2015-07-07 2021-11-16 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1
CN108026052B (zh) * 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201708193A (zh) * 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
MX2018009633A (es) * 2016-02-09 2018-12-17 Inventisbio Inc Inhibidor de indoleamina-2,3-dioxigenasa (ido).
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
US20210113598A1 (en) * 2017-08-01 2021-04-22 Deutsches Krebsforschungszentrum (DKFZ) Stiftung des öffentlichen Rechts Combination of MIDH1 Inhibitors and DNA Hypomethylating Agents (HMA)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
EP3720442B1 (en) 2018-05-16 2022-12-28 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2020001474A1 (zh) * 2018-06-26 2020-01-02 南京明德新药研发有限公司 苯并咪唑衍生物及其作为idh1抑制剂的应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
MX2023000902A (es) * 2020-07-21 2023-02-22 Daiichi Sankyo Co Ltd Combinacion farmaceutica de temozolomida e inhibidor de la enzima mutante idh1.
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
WO2010151441A1 (en) * 2009-06-23 2010-12-29 Translational Genomics Research Institute Benzamide derivatives
CN103435554A (zh) * 2013-09-06 2013-12-11 中国药科大学 2-苯氨基苯并咪唑类化合物及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
CN1161340C (zh) 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
ATE365165T1 (de) 2002-03-01 2007-07-15 Smithkline Beecham Corp Diaminopyrimidine und deren verwendung als angiogenesehemmer
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
JPWO2006038738A1 (ja) 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
US7893267B2 (en) 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
WO2009116074A2 (en) 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
SG11201605810WA (en) 2014-02-11 2016-08-30 Bayer Pharma AG Benzimidazol-2-amines as midh1 inhibitors
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
CN107108554B (zh) 2014-10-23 2020-11-06 德国癌症研究中心 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
CA2965201A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
JP2018515623A (ja) 2015-05-18 2018-06-14 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としての複素環式化合物
CA3025145A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
JP6830909B2 (ja) 2015-06-08 2021-02-17 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール
ES2877424T3 (es) 2015-07-07 2021-11-16 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
TW201708193A (zh) 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
CN109071460B (zh) 2016-03-02 2022-08-09 转化药物开发有限责任公司 氨基苯并咪唑衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
WO2010151441A1 (en) * 2009-06-23 2010-12-29 Translational Genomics Research Institute Benzamide derivatives
CN103435554A (zh) * 2013-09-06 2013-12-11 中国药科大学 2-苯氨基苯并咪唑类化合物及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells;Dan Rohle,et al.;《Science》;20130503;第340卷;第626-630页 *
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate;Lenny Dang,et al.;《Nature》;20091210;第462卷;第739-744页 *
IDH1基因在人脑胶质瘤中突变及其功能意义研究;曾飞跃.;《中国博士学位论文全文数据库·医药卫生科技辑》;20101115(第11期);E072-182 *
IDH1基因突变与胶质瘤;王国良.;《中国微侵袭神经外科杂志》;20120820;第17卷(第8期);第379-381页 *

Also Published As

Publication number Publication date
CL2016002033A1 (es) 2017-03-31
JP6534675B2 (ja) 2019-06-26
SV2016005257A (es) 2018-10-02
US20190062285A1 (en) 2019-02-28
AP2016009371A0 (en) 2016-08-31
EA201691590A1 (ru) 2017-02-28
CU24410B1 (es) 2019-05-03
UY35991A (es) 2015-09-30
PH12016501581A1 (en) 2017-02-06
CR20160361A (es) 2016-10-03
TWI666202B (zh) 2019-07-21
CN106573897A (zh) 2017-04-19
JP2017505790A (ja) 2017-02-23
CU20160120A7 (es) 2016-12-23
EP3105209A1 (en) 2016-12-21
WO2015121210A1 (en) 2015-08-20
IL246785A0 (en) 2016-08-31
DOP2016000208A (es) 2016-09-15
MX2016010474A (es) 2016-10-31
TW201613874A (en) 2016-04-16
CA2939026A1 (en) 2015-08-20
US9957235B2 (en) 2018-05-01
KR20160115991A (ko) 2016-10-06
BR112016018604A2 (pt) 2017-08-08
SG11201605810WA (en) 2016-08-30
EP3105209B1 (en) 2019-08-21
AU2015217788A1 (en) 2016-08-04
PE20170143A1 (es) 2017-03-19
US10442772B2 (en) 2019-10-15
EA031655B1 (ru) 2019-02-28
AU2015217788B2 (en) 2019-06-27
US20170197921A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
CN106573897B (zh) 作为mIDH1抑制剂的苯并咪唑-2-胺
JP6688735B2 (ja) ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
EP3209646B1 (en) Benzimidazol-2-amines as midh1 inhibitors
CN107810176B (zh) 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物
US10179123B2 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
CN107108554B (zh) 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
CN108026053A (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
CN108026052A (zh) 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
HK1236531A1 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398B (zh) 作为midh1抑制剂的苯并咪唑-2-胺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236531

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200513

Address after: Heidelberg, Germany

Patentee after: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS

Address before: Berlin

Patentee before: BAYER PHARMA AG

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190924

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236531

Country of ref document: HK